These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19331137)

  • 1. Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.
    Kolinsky K; Zhang YE; Dugan U; Heimbrook D; Packman K; Higgins B
    Anticancer Res; 2009 Jan; 29(1):91-8. PubMed ID: 19331137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models.
    Kolinsky K; Shen BQ; Zhang YE; Kohles J; Dugan U; Zioncheck TF; Heimbrook D; Packman K; Higgins B
    Mol Cancer Ther; 2009 Jan; 8(1):75-82. PubMed ID: 19139115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model.
    Higgins B; Kolinsky K; Linn M; Adames V; Zhang YE; Moisa C; Dugan U; Heimbrook D; Packman K
    Anticancer Res; 2007; 27(4B):2279-87. PubMed ID: 17695515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on capecitabine alone and in combination regimens in colorectal cancer patients.
    Silvestris N; Maiello E; De Vita F; Cinieri S; Santini D; Russo A; Tommasi S; Azzariti A; Numico G; Pisconti S; Petriella D; Lorusso V; Millaku A; Colucci G
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S46-55. PubMed ID: 21129610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
    Yanagisawa M; Fujimoto-Ouchi K; Yorozu K; Yamashita Y; Mori K
    Oncol Rep; 2009 Aug; 22(2):241-7. PubMed ID: 19578762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor activity of capecitabine in combination with irinotecan.
    Cao S; Durrani FA; Rustum YM
    Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
    Dahan L; Ciccolini J; Evrard A; Mbatchi L; Tibbitts J; Ries P; Norguet E; Mercier C; Iliadis A; Ouafik L; Lacarelle B; Seitz JF
    J Clin Oncol; 2012 Feb; 30(4):e41-4. PubMed ID: 22184401
    [No Abstract]   [Full Text] [Related]  

  • 9. Common side effects and interactions of colorectal cancer therapeutic agents.
    Holt K
    J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717
    [No Abstract]   [Full Text] [Related]  

  • 10. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
    Landherr L; Nagykálnai T
    Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
    Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
    Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
    Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J
    Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine/irinotecan combination regimens in colorectal cancer.
    Kerr DJ
    Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):27-9. PubMed ID: 12014865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
    Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
    Cartwright T; McCollum D; Boehm KA
    Am J Clin Oncol; 2010 Jun; 33(3):307-13. PubMed ID: 20375835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen.
    Ardavanis A; Kountourakis P; Mantzaris I; Malliou S; Doufexis D; Sykoutri D; Fragos I; Rigatos G
    Anticancer Res; 2008; 28(5B):3087-92. PubMed ID: 19031962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.
    Rudek MA; Dasari A; Laheru D; He P; Jin R; Walker R; Taylor GE; Jimeno A; Donehower RC; Hidalgo M; Messersmith WA; Purcell WT
    J Clin Pharmacol; 2016 Aug; 56(8):966-73. PubMed ID: 26632033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
    Fuchs CS; Marshall J; Barrueco J
    J Clin Oncol; 2008 Feb; 26(4):689-90. PubMed ID: 18235136
    [No Abstract]   [Full Text] [Related]  

  • 19. [Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].
    Kocáková I; Kocák I; Svoboda M; Nemecek R; Rehák Z; Standara M
    Klin Onkol; 2009; 22(2):73-6. PubMed ID: 19522377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.